Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

J&J’s Spravato On Track To Be A Blockbuster, Five Years In

 Johnson & Johnson’s drug for treatment-resistant depression got off to a slow start when it launched in 2019, but strong sales growth has put it on a blockbuster trajectory this year. 

Sales & Earnings Launches

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

Pfizer Advancing Once-Daily Danuglipron For Obesity

A modified-release formulation of the oral GLP-1 has been selected for development, Pfizer said. Dose-optimization studies will begin in the second half of the year.

Metabolic Disorders Research & Development

Amylyx Steps Outside Neurodegenerative Disease With New Late-Stage Asset

The company outlined plans to develop newly acquired GLP-1 antagonist avexitide. CEOs Joshua Cohen and Justin Klee talked to Scrip about the strategy.

Deals Research & Development

Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition

Chief scientific officer and president of Pfizer Research & Development Mikael Dolsten will depart the company after a successor is appointed, likely early next year.

Leadership Research & Development

Cartesian Looks To Chart The Way For CAR-T In Autoimmune Disease

A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.

Immune Disorders Clinical Trials
See All